最佳Myelofibrosis播客 (2024)

1
The Long-Term Safety of Momelotinib for Myelofibrosis: A Poster from ASH

3d ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Douglas Tremblay, MD Based on three randomized-controlled trials, the JAK inhibitor momelotinib has demonstrated clinical activity against anemia, constitutional symptoms, and splenomegaly in patients with myelofibrosis. But what do we know about its long-term safety? That’s what a recent study explor…

1
Investigating the Impact of Momelotinib on Myelofibrosis Patients: A Poster from ASH

3d ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Mary Frances McMullin, MD The MOMENTUM study evaluated the impact of the treatment option momelotinib on patient-reported outcomes, including symptom burden and overall quality of life. Joining Dr. Charles Turck to share the key findings and potential implications for myelofibrosis care is Dr. Mary Fr…

1
Bone marrow failure related to ERG insufficiency, factor 11 in vascular hyperpermeability, and new criteria for evaluating anemia in myelofibrosis 20:32

8d ago20:32

20:32

In this week's episode we’ll learn more about the role of ERG loss-of-function variants in bone marrow failure and hematological malignancies, a proposed pathway linking factor 11 activation to increased vascular permeability during inflammation, and new clinical criteria for diagnosing anemia, defining transfusion-dependence, and evaluating anemia…

1
S11 Ep23: Navigating Myelofibrosis: Updates for Community Hematologist Oncologists 25:38

18d ago25:38

25:38

In today’s episode, supported by Sobi, we had the pleasure of speaking with Aaron T. Gerds, MD, MS, and James K. McCloskey, MD, about myelofibrosis treatment advances. Dr Gerds is an assistant professor in the Department of Medicine in the School of Medicine, as well as a member of the Developmental Therapeutics Program at the Case Comprehensive Ca…

1
All Hands on Deck – Utilizing JAK Inhibitors in Myelofibrosis Care: Evidence, Timing, and Strategic Approaches 46:40

25d ago46:40

46:40

Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibition is the standard of care for patients with symptomatic myelofibrosis (MF); however, a significant number of hematologists/oncologists lack knowledge, competence, and confidence about JAK inhibitors (JAKis) in MF. These clinicians and their interdisciplinary c…

1
S11 Ep30: SUNLIGHT QOL Data Show Positive Outcomes With T rifluridine-Tipiracil Plus Bevacizumab in CRC : With Joleen Hubbard, MD 10:38

15h ago10:38

10:38

In today’s episode, supported by Taiho Pharmaceutical, we had the pleasure of speaking with Joleen Hubbard, MD, about practice-changing updates to the colorectal cancer (CRC) treatment paradigm. Dr Hubbard is a medical oncologist at Allina Health Cancer Institute in Minneapolis, Minnesota. In our exclusive interview, Dr Hubbard discussed key effica…

1
Update on fixed-dose venetoclax-obinutuzumab in previously untreated CLL; dual epi-immunotherapy in cHL; predicting treatment failure in TKI-treated CML 19:03

21h ago19:03

19:03

In this week's episode we'll learn about the updated phase 3 results on fixed-dose venetoclax plus obinutuzumab in previously untreated CLL. Then, we'll hear about dual epi-immunotherapy in classical Hodgkin lymphoma. Finally we'll explore redefining risk of treatment failure in CML. Featured Articles: Venetoclax-obinutuzumab for previously untreat…

1
S11 Ep29: Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD 20:23

1d ago20:23

20:23

In this episode of the Oncology Unplugged series, Chandler Park, MD, a genitourinary medical oncologist at Norton Cancer Institute in Louisville, Kentucky, hosted a conversation with Vivek Subbiah, MD, a medical oncologist and chief of Early-Phase Drug Development at Sarah Cannon Research Institute in Nashville, Tennessee. Dr Subbiah, an internatio…

1
Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma 57:58

1d ago57:58

57:58

Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma.…

1
Poster Pearl: Elacestrant + Abemaciclib for ER+/HER2- Metastatic Breast Cancer

3d ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Erika Hamilton, MD The ELECTRA trial is seeking to evaluate the combination of elacestrant with abemaciclib in patients with ER+/HER2- metastatic breast cancer regardless of metastatic site and ESR1 status to see if this could be an all-oral treatment option before using fulvestrant-based combinations…

1
S11 Ep28: Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing: With David R. Gandara, MD 11:29

4d ago11:29

11:29

In today’s episode, we had the pleasure of speaking with David R. Gandara, MD, about biomarker testing in lung cancer. Dr Gandara is the chief medical officer of the International Society of Liquid Biopsy, the co-director of the Center for Experimental Therapeutics in Cancer, and the senior advisor to the director at the University of California Da…

1
Episode 52. Management of Hodgkin Lymphoma in Older Adults with Dr. Andrew Evens 42:28

6d ago42:28

42:28

In this episode, we dive into the management of older adults with Hodgkin Lymphoma with Dr. Andrew Evens. Here are the key articles we discussed: 1. Comparison of ABVD versus Stanford V in older Hodgkin Lymphoma patients: https://pmc.ncbi.nlm.nih.gov/articles/PMC3906856/ 2. Outcome of older adults ECHELON-1: https://pubmed.ncbi.nlm.nih.gov/34162178…

1
Practical Perspectives: Current Management of Chronic Myeloid Leukemia 1:49:21

8d ago1:49:21

1:49:21

Drs Bhavana (Tina) Bhatnagar, Amanda Blackmon, Jorge Cortes, Michael J Mauro and Neil P Shah discuss recent updates on clinical treatment strategies for chronic myeloid leukemia.由Neil Love, MD

1
S11 Ep27: Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD 11:33

8d ago11:33

11:33

In today’s episode, we had the pleasure of speaking with Alan P. Venook, MD, about recent updates to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for gastrointestinal (GI) cancers. Dr Venook holds the Madden Family Distinguished Professorship in Medical Oncology and Translational Research and is a professor in the D…

1
Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies 20:40

9d ago20:40

20:40

In this episode, Caitlin Costello, MD, discusses important topics related to relapsed/refractory (R/R) multiple myeloma (MM), including: 3 bispecific antibodies approved for the treatment of R/R MM that target BCMA or GPRC5D The role of bispecific antibodies in R/R MM Safety considerations for patients while receiving a bispecific antibody Emerging…

1
S11 Ep26: Phase 1 Trials Provide Oncology Fellows With Valuable Clinical Research Experience: With Samuel A. Kareff, MD, MPH 14:08

11d ago14:08

14:08

In today’s episode, we had the pleasure of speaking with Samuel A. Kareff, MD, MPH, about the intersections between early-phase clinical research and meaningful mentorship experiences during oncology/hematology fellowship. Dr Kareff is a medical oncologist and hematologist at the Eugene M. and Christine E. Lynn Cancer Institute, part of Baptist Hea…

1
Oncology Today with Dr Neil Love: Peripheral T-Cell Lymphoma 46:32

15d ago46:32

46:32

Dr Stephen Horwitz from Memorial Sloan Kettering Cancer Center in New York, New York, discusses management strategies for previously untreated and relapsed peripheral T-cell lymphomas.由Neil Love, MD

1
S11 Ep25: FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL 8:17

15d ago8:17

8:17

In today’s episode, supported by Citius Pharmaceuticals, we had the pleasure of speaking with Francine Foss, MD, to discuss the FDA approval of denileukin diftitox-cxdl (Lymphir) for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL) who have received 1 or more prior systemic therapies. Dr Foss is a professor of med…

1
Platelet glycoprotein receptor VI in abdominal aortic aneurysms, TP53 mutations in 5q-deleted myelodysplastic syndrome, and immunostimulatory cytokine plus CAR T-cell therapy in acute lymphoblastic leukemia ... 18:59

15d ago18:59

18:59

In this week's episode, we'll learn about the role of a platelet-specific glycoprotein receptor in abdominal aortic aneurysm formation, the influence of TP53 mutations on outcomes for patients with 5q-deleted myelodysplastic syndrome, and a rational combination treatment intended to produce more durable responses in patients with refractory B-cell …

1
S11 Ep24: How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD 17:21

16d ago17:21

17:21

Dr Patil emphasized the significance of the phase 3 CROWN trial (NCT03052608), which compared lorlatinib (Lorbrena) with crizotinib (Xalkori) in patients with ALK-positive metastatic NSCLC. With a hazard ratio of 0.19 (95% CI, 0.13-0.27) for progression-free survival, the trial demonstrated lorlatinib’s superior intracranial control and long-term e…

1
Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations 28:28

16d ago28:28

28:28

In this episode, Thor R. Halfdanarson, MD, and Jonathan Strosberg, MD, discuss important topics related to gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including: The diagnosis and typical presenting symptoms of GEP-NETs Findings from recent key phase III studies including NETTER-2 and CABINET Recommendations for treatment sequencing No…

1
Enhancing Outcomes in Relapsed/Refractory B-ALL with CAR T-Cell Therapy

16d ago

—

Host: Gates B. Colbert, MD Guest: Ryan Cassaday, MD According to the available long-term data, CAR T-cell therapy boosts overall survival and durable remission rates in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Given this data, it’s important to know how we can best identify appropriate patients for this approac…

1
Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 1 of a 3-Part Series 58:58

22d ago58:58

58:58

Dr Matthew S Davids from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews current available data and ongoing investigational treatment approaches for chronic lymphocytic leukemia.由Neil Love, MD

1
S11 Ep22: FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma 12:28

22d ago12:28

12:28

In today’s episode, supported by Servier Pharmaceuticals, we had the pleasure of speaking with Jennie W. Taylor, MD, MPH, about the FDA approval of vorasidenib (Voranigo) for patients with IDH-positive grade 2 astrocytoma or oligodendroglioma. Dr Taylor is an associate professor of clinical neurology at the University of California, San Francisco (…

1
Using NGS to refine risk stratification in T-ALL; a novel gene therapy approach in severe α-thalassemia; molecular taxonomy of MDS 21:48

22d ago21:48

21:48

In this week's episode we'll learn about refining risk stratification in T-cell acute lymphoblastic leukemia, or ALL. After that, we'll discuss a novel gene therapy approach in severe alpha-thalassemia. Investigators describe an innovative mouse model and an effective gene therapy approach, renewing prospects for the development of novel strategies…

1
S11 Ep21: Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD 11:59

25d ago11:59

11:59

In our exclusive interview, Dr Dietrich discussed key efficacy findings from the 18-month follow-up of the phase 2 VISION trial (NCT02864992), which evaluated the efficacy of tepotinib (Tepmetko) in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations. Additionally, Dr Dietrich emphasized important safety considerations…

1
All Hands on Deck in Cervical Cancer Care: Screening, Treatment, and Equity Strategies to Improve Patient Lives 1:00:36

25d ago1:00:36

1:00:36

The reduced incidence of cervical cancer over the past few decades was primarily due to robust screening guidelines and vaccinations. However, despite the proliferation of screening programs, the diagnosis of cervical cancer is associated with inefficiencies and inconsistencies and has not decreased cervical cancer incidence further over the past d…

1
S11 Ep20: FDA Approval Insights: Perioperative Durvalumab for Resectable NSCLC 15:09

29d ago15:09

15:09

In today’s episode, supported by AstraZeneca, we had the pleasure of speaking with Sandip P. Patel, MD, and Brendon M. Stiles, MD, about the FDA approval of perioperative durvalumab (Imfinzi) for patients with resectable non–small cell lung cancer (NSCLC). Dr Patel is a professor of medicine in the Department of Medicine at the University of Califo…

1
A novel tripartite fusion drives treatment resistance in atypical APL; managing iTTP without TPE; hope for motherhood after allogeneic HCT 18:30

29d ago18:30

18:30

In this week's episode we’ll discuss a novel tripartite fusion drives treatment resistance in acute promyelocytic leukemia. In some patients with atypical APL, these novel retinoic acid receptor gene fusions result in truncation of the ligand binding domain of the retinoic acid receptor protein, resulting in non-responsiveness to treatment with all…

1
Naval Daver, MD, Tapan Kadia, MD - Opportunity Knocks in AML: Guidance on Achieving Truly Personalized Care in Challenging Populations with Modern Therapeutics 1:03:04

30d ago1:03:04

1:03:04

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/HGC865. CM…

1
Shannon N. Westin, MD, MPH, Ramez N. Eskander, MD - Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements ... 1:06:30

30d ago1:06:30

1:06:30

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJE8…

1
Shannon N. Westin, MD, MPH, Ramez N. Eskander, MD - Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements ... 1:06:30

30d ago1:06:30

1:06:30

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJE8…

1
Naval Daver, MD, Tapan Kadia, MD - Opportunity Knocks in AML: Guidance on Achieving Truly Personalized Care in Challenging Populations with Modern Therapeutics 1:03:04

30d ago1:03:04

1:03:04

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/HGC865. CM…

1
S11 Ep19: Immunotherapy Advances Expand the SCLC Treatment Paradigm: With Chandler Park, MD, and Tejas Patil, MD 15:18

30d ago15:18

15:18

In part 2 of this 3-part Oncology Unplugged series, Chandler Park, MD, a genitourinary medical oncologist at Norton Cancer Institute in Louisville, Kentucky, and Tejas Patil, MD, an assistant professor of medical oncology at the University of Colorado School of Medicine in Aurora, discussed the evolving small cell lung cancer (SCLC) treatment parad…

1
Momelotinib vs. Ruxolitinib: Comparing Efficacy in Myelofibrosis and Anemia Patients

1M ago

—

Host: Matt Birnholz, MD The SIMPLIFY-2 trial compared the efficacy of momelotinib to best available therapy, which was primarily continued ruxolitinib, in patients with myelofibrosis and anemia who were previously treated with a JAK inhibitor. According to the findings, momelotinib potentially offers better outcomes and a more comprehensive managem…

1
ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers 30:45

1M ago30:45

30:45

In this episode, listen to Ana Oaknin, MD, PhD and Alexandra Leary, MD, PhD, share their clinical insights and takeaways on key updates and new data presented for ovarian, endometrial, and cervical cancer at the ESMO 2024 annual congress including: Phase III PRIMA/ENGOT-OV26/GOG-3012 Final OS Results: Niraparib as First-Line Maintenance in Advanced…

1
S11 Ep18: Board Review Resources 2024 15:25

1M ago15:25

15:25

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University…

1
A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance 32:48

1M ago32:48

32:48

In this episode, listen to Matthew S. Davids, MD, MMSc, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including: Contemporary treatment paradigms for patients with CLL Safety and efficacy of current regimens Molecular testing, including when and how to test for BTK inhibitor res…

1
Episode 51. Venetoclax in AML with Dr. Andrew Wei 56:57

1M ago56:57

56:57

In this episode, we discuss the history of venetoclax in AML, along with key clinical trials that have shaped its current use in AML. Here are the trials discussed in this episode: 1. VIALE-A study: https://www.nejm.org/doi/full/10.1056/NEJMoa2012971 2. 10 day Decitabine plus venetoclax for ND AML https://www.thelancet.com/journals/lanhae/article/P…

1
S11 Ep17: How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD 13:01

1M ago13:01

13:01

In today’s episode, we had the pleasure of speaking with Rory Shallis, MD, an assistant professor of medicine and hematology at Yale School of Medicine, part of Yale New Haven Health in Connecticut. Shallis sat down with us to share some of the research that has been generated in myelodysplastic syndrome (MDS) over the past year or so, touching on …

值得一听的播客

Myelofibrosis播客

值得一听的播客

快速参考指南